Ingevity (NGVT) reported Q4 adjusted earnings late Tuesday of $0.95 per diluted share, compared with a loss of $0.20 a year earlier.
Four analysts polled by FactSet expected non-GAAP EPS of $0.31.
Net sales in the three months ended Dec. 31 fell to $298.8 million from $371.7 million a year earlier.
Three analysts surveyed by FactSet expected $310.9 million.
The company expects 2025 sales of $1.3 billion to $1.4 billion.
Four analysts surveyed by FactSet project $1.45 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.